Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 50-Day Moving Average – Should You Sell?

Spero Therapeutics, Inc. (NASDAQ:SPRO)’s stock price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $2.35 and traded as high as $2.36. Spero Therapeutics shares last traded at $2.32, with a volume of 376,407 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on SPRO shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a report on Thursday, January 22nd. Wall Street Zen raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, January 11th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Spero Therapeutics has a consensus rating of “Reduce”.

Spero Therapeutics Trading Up 5.7%

The stock has a market capitalization of $145.92 million, a PE ratio of -3.28 and a beta of 1.45. The firm has a 50-day moving average price of $2.36 and a 200-day moving average price of $2.27.

Insiders Place Their Bets

In other news, insider Esther Rajavelu sold 87,917 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.36, for a total transaction of $207,484.12. Following the completion of the transaction, the insider directly owned 1,012,091 shares of the company’s stock, valued at $2,388,534.76. This represents a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Spero Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Invesco Ltd. bought a new position in Spero Therapeutics during the second quarter valued at $43,000. Dimensional Fund Advisors LP bought a new stake in shares of Spero Therapeutics in the third quarter valued at $55,000. Millennium Management LLC purchased a new position in shares of Spero Therapeutics during the 4th quarter valued at $56,000. Assenagon Asset Management S.A. purchased a new position in shares of Spero Therapeutics during the 3rd quarter valued at $70,000. Finally, Quadrature Capital Ltd bought a new position in shares of Spero Therapeutics during the 4th quarter worth $88,000. Institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.